Medicines in pregnancy [version 1; peer review: 3 approved]
Medicine use in pregnancy is extremely common, but there are significant knowledge gaps surrounding the safety, dosage and long-term effects of drugs used. Pregnant women have been purposively excluded from clinical trials of the majority of treatments for conditions that may occur concurrently with...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2019-06-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/8-911/v1 |
_version_ | 1818500582189563904 |
---|---|
author | Sarah JE Stock Jane E Norman |
author_facet | Sarah JE Stock Jane E Norman |
author_sort | Sarah JE Stock |
collection | DOAJ |
description | Medicine use in pregnancy is extremely common, but there are significant knowledge gaps surrounding the safety, dosage and long-term effects of drugs used. Pregnant women have been purposively excluded from clinical trials of the majority of treatments for conditions that may occur concurrently with pregnancy. There is minimal information on the pharmacokinetics of many existing treatments and no systematic capture of long-term outcome data to help inform choices. Treatments commonly used in pregnancy are thus often old and untested, not optimised in dose, and prescribed off-label without adequate safety information. In addition, there has been a staggering lack of investment in drug development for obstetric conditions for decades. This is a major public health concern, and pregnancy complications are the leading cause of mortality in children under five years old globally, and health in pregnancy is a major determinant of women’s long-term health and wellbeing. There is an acute need for adequate investment and legislation to boost inclusion of pregnant women in clinical studies, capture high-quality information on medication use in pregnancy in general, and encourage new medicinal product development for obstetric conditions. |
first_indexed | 2024-12-10T20:44:42Z |
format | Article |
id | doaj.art-ed831d3e3f8346c5bc2771b4cbf3c0ec |
institution | Directory Open Access Journal |
issn | 2046-1402 |
language | English |
last_indexed | 2024-12-10T20:44:42Z |
publishDate | 2019-06-01 |
publisher | F1000 Research Ltd |
record_format | Article |
series | F1000Research |
spelling | doaj.art-ed831d3e3f8346c5bc2771b4cbf3c0ec2022-12-22T01:34:16ZengF1000 Research LtdF1000Research2046-14022019-06-01810.12688/f1000research.17535.119177Medicines in pregnancy [version 1; peer review: 3 approved]Sarah JE Stock0Jane E Norman1Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Nine Edinburgh BioQuarter, 9 Little France Road, Edinburgh, EH16 4UX, UKMRC Centre for Reproductive Health, University of Edinburgh, Edinburgh BioQuarter, Edinburgh, EH16 4SA, UKMedicine use in pregnancy is extremely common, but there are significant knowledge gaps surrounding the safety, dosage and long-term effects of drugs used. Pregnant women have been purposively excluded from clinical trials of the majority of treatments for conditions that may occur concurrently with pregnancy. There is minimal information on the pharmacokinetics of many existing treatments and no systematic capture of long-term outcome data to help inform choices. Treatments commonly used in pregnancy are thus often old and untested, not optimised in dose, and prescribed off-label without adequate safety information. In addition, there has been a staggering lack of investment in drug development for obstetric conditions for decades. This is a major public health concern, and pregnancy complications are the leading cause of mortality in children under five years old globally, and health in pregnancy is a major determinant of women’s long-term health and wellbeing. There is an acute need for adequate investment and legislation to boost inclusion of pregnant women in clinical studies, capture high-quality information on medication use in pregnancy in general, and encourage new medicinal product development for obstetric conditions.https://f1000research.com/articles/8-911/v1 |
spellingShingle | Sarah JE Stock Jane E Norman Medicines in pregnancy [version 1; peer review: 3 approved] F1000Research |
title | Medicines in pregnancy [version 1; peer review: 3 approved] |
title_full | Medicines in pregnancy [version 1; peer review: 3 approved] |
title_fullStr | Medicines in pregnancy [version 1; peer review: 3 approved] |
title_full_unstemmed | Medicines in pregnancy [version 1; peer review: 3 approved] |
title_short | Medicines in pregnancy [version 1; peer review: 3 approved] |
title_sort | medicines in pregnancy version 1 peer review 3 approved |
url | https://f1000research.com/articles/8-911/v1 |
work_keys_str_mv | AT sarahjestock medicinesinpregnancyversion1peerreview3approved AT janeenorman medicinesinpregnancyversion1peerreview3approved |